AU - Aghasadeghi, Mohammad Reza AU - Sadat, Sayyed Mahdi AU - Bahramali, Golnar AU - Hekmat, Soheila AU - Motevali, Fatemeh AU - Alizadeh, Shahadeh AU - Kadkhodaeian, Somayeh AU - Rouhvand, Farzin TI - Evaluating novel adjuvant systems for the induction of humeral and cellular immune responses in hepatitis C virus capsid protein immunization PT - JOURNAL ARTICLE TA - KAUMS JN - KAUMS VO - 14 VI - 1 IP - 1 4099 - http://feyz.kaums.ac.ir/article-1-870-en.html 4100 - http://feyz.kaums.ac.ir/article-1-870-en.pdf SO - KAUMS 1 AB  - Background: As a worldwide problem, hepatitis C Virus (HCV) infection similar to HIV and vaccine studies on HCV is among the hottest research topics in the field. Such a vaccine should elicit strong humeral and cellular responses against HCV antigens (Ags). The major aim of the present study was to compare and optimize the responses against HCV core protein (HCVcp) immunization formulated in novel human compatible adjuvants. Materials and Methods: BALB/c mice were immunized by HCVcp, purified in native conditions and in different adjuvant formulation in separate following groups: Ag+CpG, Ag+M720 (Montanide ISA 720), Ag+F127 (Pluronic acid) and cocktails of Ag+F127+CpG and Ag+M720+CpG. ELISA-based assays were used to analyze IgG, cytokine and CTL responses. Results: The M720 (+CpG) immunized mice developed the highest HCVcp-specific titrations of total IgG,IgG1, 2a, 2b, and that of IFN-γ and IL-4 cytokines. HCVcp-specific-CTLs against relevant MHC class I peptides were detected only for Ag+M720+CpG, Ag+M720, and Ag+CpG groups, could be blocked by antimouse-CD8 antibodies and were stable for one year post-immunization. Conclusions: The M720 formulation of HCVcp (with a synergistic effect by inclusion of CpG) induces equally strong Th1/Th2 responses and stable CTLs. CP - IRAN IN - Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, I. R. Iran LG - eng PB - KAUMS PG - 26 PT - Research YR - 2010